IFNB1 and neoplasm: Remarkably, mice that had their primary tumor treated with the p19Arf/IFN-β combination showed improved tumor control at the challenge site even when compared to IFN-β single treatment, showing superior immune protection by the combined p19Arf and IFN-β in situ gene therapy [358].